⚠ Evidence warning: Clinical trials or other evidence do not support the claims that St. John's wort helps anxiety, neuropathic pain and menopausal mood and that whole-plant extracts outperform purified isolates. This page keeps it as a report of what people, websites or other media say.

St. John's Wort — Benefits Deep Dive

Benefits — scientific infographic poster

Hypericum perforatum — the bright-yellow European wildflower that blooms around the summer solstice — is the single most rigorously studied herbal antidepressant in modern medicine. Multiple Cochrane reviews (most recently Linde 2008, pooling 29 randomized trials and over 5,000 patients) have concluded that hypericum extracts are similarly effective as standard antidepressants, including selective serotonin reuptake inhibitors (SSRIs), in major depression, with fewer side effects. The latest of them adds that more favourable results from German-speaking countries complicate the interpretation, and a 2017 meta-analysis states its own conclusion for mild-to-moderate depression. The therapeutic profile depends on the synergy of three principal compound classes: hyperforin (multi-monoamine reuptake inhibition through TRPC6 channel activation), hypericin (photodynamic and monoamine oxidase (MAO)-modulating activity), and a rich flavonoid fraction (antioxidant and gamma-aminobutyric acid-receptor binding). Four deep-dive pages below explore the major benefit domains — depression, mood and seasonal affective disorder, topical antiviral and wound-healing applications, and the most consequential and dangerous aspect of this herb's use: its potent induction of CYP450 enzymes and P-glycoprotein, which makes it the most-interacting herb in common clinical use.

⚠ CRITICAL SAFETY WARNING — Drug Interactions

St. John's Wort has the most extensive and clinically significant drug-interaction profile of any commonly used medicinal herb. Through induction of CYP3A4, CYP1A2, CYP2C9, and P-glycoprotein, it can reduce blood levels of many prescription drugs (CYP3A4 alone is involved in the metabolism of more than 50% of all drugs, per Moore 2000) — including oral contraceptives (documented contraceptive failures and unintended pregnancies), warfarin, cyclosporine and tacrolimus (acute organ rejection has been reported), human immunodeficiency virus (HIV) protease inhibitors (treatment failure with viral resistance), digoxin, statins, anticoagulants, and chemotherapy agents. Combined with selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), triptans, tramadol, or monoamine oxidase inhibitors (MAOIs), it can cause potentially fatal serotonin syndrome. The U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and Health Canada have all issued formal warnings. Interaction checks by healthcare providers, pharmacists, and surgical teams depend on their knowing St. John's Wort is being taken, including before a new medication or procedure. See the Critical Drug Interactions deep-dive for the comprehensive interaction table.

Deep-Dive Articles

🌤️

Depression

The single most studied indication. Linde et al. 2008 Cochrane meta-analysis of 29 trials and 5,489 patients concluded hypericum extracts are similarly effective as standard selective serotonin reuptake inhibitor and tricyclic antidepressants in major depression with fewer side effects, and noted that more favourable results from German-speaking countries complicate the interpretation. Standardized extracts, the Hypericum LI 160 trials (including a 2002 US trial that did not beat placebo), the pivotal mechanism of multi-monoamine reuptake inhibition via hyperforin's activation of TRPC6 ion channels, and the 4-6 week onset window that distinguishes botanical from pharmaceutical treatment.

Read the deep dive →
☀️

Mood & Seasonal Depression

Wheatley's 1999 postal survey in seasonal affective disorder (SAD), the photoreceptor-mediated hypericin mood hypothesis, the curious paradox of an herb whose name and traditional harvest are tied to the summer solstice being clinically useful for winter depression, comparison to bright-light therapy (10,000 lux), combination protocols, and the mild-winter-depression and sub-syndromal sub-SAD applications that fall short of full Diagnostic and Statistical Manual of Mental Disorders (DSM) seasonal affective disorder criteria but still meaningfully impair quality of life.

Read the deep dive →
🩹

Antiviral & Wound Healing

The ancient European wound oil (Oleum Hyperici, "St. John's Oil," "Red Oil") prepared by infusing fresh flowers in olive oil and sun-curing for weeks. Hypericin's photodynamic mechanism against enveloped viruses including herpes simplex virus types 1 and 2 (HSV-1, HSV-2) and human papillomavirus (HPV). Hypericin topical photodynamic therapy (PDT) in dermatology. The herb's traditional use for nerve pain (trigeminal neuralgia, post-herpetic neuralgia, sciatica), bacterial skin infections including methicillin-resistant Staphylococcus aureus (MRSA), and the burn and bruise applications that predated its antidepressant fame by centuries.

Read the deep dive →
💊

Critical Drug Interactions

The page that sets out this herb's drug interactions and safety facts. A comprehensive table of CYP3A4, CYP1A2, CYP2C9, and P-glycoprotein-induced interactions; CYP3A4 alone is involved in the metabolism of more than 50% of all drugs. Documented contraceptive failures, organ-rejection case series, human immunodeficiency virus antiretroviral failure, warfarin international normalized ratio (INR) collapse, the serotonin syndrome risk with selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SNRI) combination, the U.S. Food and Drug Administration, European Medicines Agency, and Health Canada warning histories, and the 5-day pre-surgical discontinuation protocol.

Read the deep dive →
⚠️

Hyperforin and Drug Interactions

Why drug levels fall, how the effect follows hyperforin content, and the case reports behind the warnings.

Read the deep dive →

Back to Table of Contents

Table of Contents

  1. Deep-Dive Articles
  2. Why St. John's Wort Produces Effects (Multi-Target Mechanism)
  3. What Is Known About Pregnancy and Breastfeeding
  4. Key Research Papers
  5. External Authoritative Resources
  6. Connections
  7. Featured Videos

Why St. John's Wort Produces Effects (Multi-Target Mechanism)

Conventional pharmaceutical antidepressants are designed as single-target drugs — a selective serotonin reuptake inhibitor selectively inhibits the serotonin transporter, a serotonin-norepinephrine reuptake inhibitor inhibits serotonin and norepinephrine transporters, a monoamine oxidase inhibitor blocks monoamine oxidase. The single-target design simplifies regulatory approval, dosing, and clinical trial interpretation, but it also limits efficacy in patients whose depression is driven by mechanisms other than the targeted neurotransmitter pathway. St. John's Wort is fundamentally different: it is a whole-plant extract whose therapeutic effect emerges from the synergistic interaction of dozens of bioactive compounds acting on multiple molecular targets simultaneously.

Three principal compound classes account for most of the documented activity:

  1. Hyperforin — the multi-monoamine reuptake inhibitor. Hyperforin is a phloroglucinol derivative discovered to be the most pharmacologically significant hypericum constituent (overturning the earlier assumption that hypericin was the active principle). Unlike pharmaceutical antidepressants that bind to neurotransmitter transporters at the substrate site, hyperforin works through an unusual mechanism: it activates the TRPC6 (Transient Receptor Potential Cation Channel C6) ion channel, raising intracellular sodium concentration, which then dissipates the sodium gradient that powers presynaptic reuptake of serotonin, norepinephrine, dopamine, gamma-aminobutyric acid (GABA), and L-glutamate. This is effectively a non-selective reuptake inhibition of five neurotransmitters from a single molecular interaction — explaining why hypericum's antidepressant effect resembles the broadest-spectrum monoamine reuptake inhibitors while also producing GABAergic anxiolytic effects that pure selective serotonin reuptake inhibitors do not. Hyperforin is also a potent inducer of the cytochrome P450 3A4 (CYP3A4) enzyme and P-glycoprotein transporter via activation of the pregnane X receptor (PXR), which is the molecular root of the herb's drug-interaction profile.
  2. Hypericin — the photodynamic and monoamine-oxidase-modulating naphthodianthrone. Hypericin is the red-pigmented compound that gives the traditional infused oil its dark crimson color and is the primary marker used to standardize commercial extracts (typically standardized to 0.3% hypericin). It is a photosensitizer: when activated by visible light, hypericin generates singlet oxygen and other reactive oxygen species that can damage enveloped viral particles, bacterial membranes, and dysplastic cells. This photodynamic mechanism underlies the topical antiviral and photodynamic therapy applications against herpes simplex virus, human papillomavirus, and certain skin cancers. Hypericin also weakly inhibits monoamine oxidase (MAO-A) in vitro, though the clinical relevance of this effect at oral therapeutic doses is debated. Hypericin is the source of the photosensitivity warning — some patients on high-dose hypericum develop sunburn-like rashes after sun exposure.
  3. Flavonoids and biflavonoids — antioxidant and GABAergic. Hypericum extracts contain a rich array of flavonoids (quercetin, rutin, hyperoside, isoquercitrin) and biflavonoids (amentoflavone, biapigenin). Amentoflavone in particular binds to the benzodiazepine binding site on the gamma-aminobutyric acid-A receptor and contributes to the herb's anxiolytic effects without the sedation or dependence liability of benzodiazepines. The flavonoids also provide direct antioxidant activity and contribute to anti-inflammatory effects via NF-kB inhibition. Importantly, the flavonoids appear to enhance the bioavailability and central nervous system (CNS) penetration of hyperforin and hypericin, which is why whole-plant extracts consistently outperform purified isolates in clinical trials.

The multi-target mechanism explains both the therapeutic breadth of the herb (effects observed in depression, anxiety, seasonal affective disorder, menopausal mood symptoms, neuropathic pain) and the clinical observation that hypericum is often well tolerated by patients who could not tolerate individual selective serotonin reuptake inhibitor or tricyclic medications. It also explains the worst feature of the herb — hyperforin activates the pregnane X receptor (Moore 2000), which induces cytochrome P450 3A4 and P-glycoprotein system-wide, producing the most extensive drug-interaction profile of any commonly used herbal product. Hyperforin's mood effects are attributed to a different target, the TRPC6 channel and the sodium gradient (Leuner 2007), so these are two separate actions of one molecule. The fourth deep-dive page sets out those interactions in full.

How drug interactions follow hyperforin content. The interaction depends on how much hyperforin an extract delivers. A 2006 systematic review of 31 clinical studies found that all 19 studies of high-hyperforin extracts (more than 10 mg of hyperforin a day) had results consistent with induction of CYP3A, the enzyme group that includes cytochrome P450 3A4, while the three studies of low-hyperforin extracts (under 4 mg a day) showed no significant effect on it. A 2020 review states that the degree of cytochrome P450 3A4 induction correlates significantly with hyperforin content. In a 2019 open-label study of 20 healthy volunteers, a low-hyperforin extract showed no pharmacokinetic interaction with the enzymes and the P-glycoprotein transporter tested, apart from a weak rise in dextromethorphan exposure. So the daily amount of hyperforin, not the hypericin figure alone, is the number these studies turn on. The low-dose evidence is limited: the 2006 review asks for more studies, and most authors of the 2019 and 2020 papers are employees of a manufacturer of these products. These studies measured drug metabolism, not serotonin effects, so they do not address the serotonin syndrome risk described above.

What the depression trials report. The trial results are not uniform. The 2008 Cochrane review pooled 29 trials (5,489 patients) and found extracts better than placebo in major depression and similarly effective as standard antidepressants, with fewer dropouts because of side effects. Two large US trials in major depression came out differently on their main measures. In 2001, 200 outpatients took an extract or placebo for 8 weeks; the main depression score did not differ between the groups, remission was 14.3% against 4.9% but low overall, and the authors concluded the extract "was not effective". In 2002, 340 outpatients took an extract, the drug sertraline or placebo for 8 weeks; neither the extract nor sertraline beat placebo on the two main measures (full response 23.9%, 24.8% and 31.9% on placebo), and the authors note the trial may have had low ability to detect a difference. Later reviews again report benefit: one of 27 trials (3,808 patients) against selective serotonin reuptake inhibitors found comparable response and remission and lower dropout in mild-to-moderate depression, with every study lasting only 4 to 12 weeks. Another, of 35 studies, rated the evidence moderate because of unexplained differences between studies.

Back to Table of Contents

What Is Known About Pregnancy and Breastfeeding

The U.S. National Center for Complementary and Integrative Health states that St. John's Wort may be unsafe during pregnancy because it may increase the risk of birth defects, and that breastfed infants of mothers who take it can experience colic, drowsiness and lethargy.

Back to Table of Contents

Key Research Papers

  1. Linde K, Berner MM, Kriston L (2008). St John's wort for major depression. Cochrane Database of Systematic Reviews, Issue 4. CD000448. The meta-analysis pooling 29 trials and 5,489 patients — concluded hypericum extracts are superior to placebo in major depression, similarly effective as standard antidepressants and have fewer side effects, and that country of origin and precision complicate the interpretation. — PubMed PMID: 18843608
  2. Müller WE (2003). Current St John's wort research from mode of action to clinical efficacy. Pharmacological Research, 47(2):101-9. A review reporting that hyperforin plays an important role in the extract and reduces neurotransmitter uptake by affecting the sodium gradient. — PubMed PMID: 12543057
  3. Leuner K, Kazanski V, Müller M, Essin K, Henke B, Gollasch M, Harteneck C, Müller WE (2007). Hyperforin--a key constituent of St. John's wort specifically activates TRPC6 channels. FASEB Journal, 21(14):4101-11. The paper that identified TRPC6 as hyperforin's molecular target. — PubMed PMID: 17666455
  4. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, Collins JL, Kliewer SA (2000). St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proceedings of the National Academy of Sciences of the United States of America, 97(13):7500-2. The molecular mechanism (pregnane X receptor activation by hyperforin) driving the herb's extensive drug-interaction profile. — PubMed PMID: 10852961
  5. Wheatley D (1999). Hypericum in seasonal affective disorder (SAD). Current Medical Research and Opinion, 15(1):33-7. A postal survey of Seasonal Affective Disorder Association members, before and after eight weeks of Hypericum, 168 people alone and 133 with light therapy; it had no placebo group. — PubMed PMID: 10216809
  6. Klemow KM, Bartlow A, Crawford J, Kocher N, Shah J, Ritsick M (2011). Medical Attributes of St. John's Wort (Hypericum perforatum). In Herbal Medicine: Biomolecular and Clinical Aspects, 2nd edition. The comprehensive monograph covering the botany, traditional use, active compounds (hyperforin, hypericin, flavonoids), pharmacology, clinical trials, and safety profile in one authoritative chapter. — doi:10.1201/b10787-12
  7. Whitten DL, Myers SP, Hawrelak JA, Wohlmuth H (2006). The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials. British Journal of Clinical Pharmacology, 62(5):512-26. — PubMed PMID: 17010103
  8. Nicolussi S, Drewe J, Butterweck V, Meyer Zu Schwabedissen HE (2020). Clinical relevance of St. John's wort drug interactions revisited. British Journal of Pharmacology, 177(6):1212-1226. Three of the four authors are employees of a manufacturer of a St. John's Wort product. — PubMed PMID: 31742659
  9. Zahner C, Kruttschnitt E, Uricher J, Lissy M, Hirsch M, Nicolussi S, Krähenbühl S, Drewe J (2019). No Clinically Relevant Interactions of St. John's Wort Extract Ze 117 Low in Hyperforin With Cytochrome P450 Enzymes and P-glycoprotein. Clinical Pharmacology & Therapeutics, 106(2):432-440. An open-label study of 20 healthy volunteers; five of the eight authors are employees of the extract's manufacturer. — PubMed PMID: 30739325
  10. Shelton RC, Keller MB, Gelenberg A, Dunner DL, Hirschfeld R, Thase ME, Russell J, Lydiard RB, Crits-Cristoph P, Gallop R, Todd L, Hellerstein D, Goodnick P, Keitner G, Stahl SM, Halbreich U (2001). Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA, 285(15):1978-86. — PubMed PMID: 11308434
  11. Hypericum Depression Trial Study Group (2002). Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA, 287(14):1807-14. — PubMed PMID: 11939866
  12. Ng QX, Venkatanarayanan N, Ho CY (2017). Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis. Journal of Affective Disorders, 210:211-221. — PubMed PMID: 28064110
  13. Maher AR, Hempel S, Apaydin E, Shanman RM, Booth M, Miles JN, Sorbero ME (2016). St. John's Wort for Major Depressive Disorder: A Systematic Review. Rand Health Quarterly, 5(4):12. — PubMed PMID: 28083422

PubMed Topic Searches

  1. PubMed: St. John's Wort Cochrane reviews of major depression
  2. PubMed: Hyperforin and the TRPC6 mechanism
  3. PubMed: PXR / CYP3A4 mechanism
  4. PubMed: Klemow monograph

Back to Table of Contents

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents